4-month TB treatment for children
Tuberculosis

Children with TB cannot wait: MSF urges countries to roll out shorter treatment

Key Takeaways

  • A study in Uganda and the Philippines shows the WHO-recommended 4-month treatment for children with non-severe Tuberculosis (TB) can be rolled out in routine primary healthcare settings.
  • Up to 74% of children with TB overall, and up to 89% in primary healthcare settings, are eligible for the shorter regimen.
  • Of 214 children in the study, 95% successfully completed treatment.
  • The 4-month regimen has been recommended by WHO since 2022, but uptake has been slow in many high-burden countries.
  • Doctors Without Borders (MSF) calls on governments, donors and global health partners to go beyond policy adoption, including by investing in training, diagnostics and child-friendly medicines.
4-month TB treatment for children
MSF doctor Dr. Maham Khalid is examining four-year-old Ahmad during a consultation at the MSF-supported Programmatic Management of Drug-Resistant Tuberculosis (PMDT) site in Gujranwala, Punjab.
MSF

At the Union World Conference on Lung Health in Rio de Janeiro, MSF) released the outcomes from a study conducted in Uganda and the Philippines showing that the World Health Organisation (WHO)-recommended 4-month treatment for children with non-severe tuberculosis (TB) can be successfully rolled out in routine primary healthcare settings. MSF calls on governments, donors and global health partners to move beyond policy adoption and accelerate the implementation of this child-friendly treatment regimen while strengthening diagnosis, prevention and care for all children affected by TB.

How many children are eligible for the shorter TB regimen?

The study shows that up to 74% of children with TB overall, and up to 89% in primary healthcare settings, are eligible for the shorter regimen. That implementation is feasible with high treatment success rates. This would offer a more person-centred approach to care while reducing the burden of treatment on children, their families and health systems.

4-month TB treatment for children
MSF doctor Hafsa Fatima is reviewing the X-ray of a patient during the pediatric clinic at the MSF-supported Programmatic Management of Drug-Resistant Tuberculosis (PMDT) site in Gujranwala, Punjab. In this clinic, the MSF team screens all children under fourteen from families of registered patients at the MSF facility. Children who diagnosed with TB start treatment at the same facility. 
MSF

Why has uptake of the 4-month TB regimen been slow?

Despite WHO recommending the 4-month regimen since 2022, uptake has been slow in many high-burden countries. One important challenge has been the need to identify children with non-severe TB who can safely benefit from this shorter treatment, a process that requires clinical assessment and, where available, chest X-ray (CXR) evaluation. The new MSF findings provide practical evidence that these challenges can be overcome in routine programme settings.

What the study’s principal investigator says about the 4-month regimen

“The 4-month treatment regimen for children with non-severe, drug-susceptible TB uses the same medicines, including child-friendly formulations, but substantially reduces the burden on children and caregivers,” said Valentina Carnimeo, Principal Investigator of the MSF multi-country TB study. “Fewer months of treatment means fewer clinic visits, less disruption to family life, lower costs for caregivers and health systems, and fewer days exposed to potential adverse effects. The evidence is clear: countries can confidently implement this regimen in routine care, and children should not have to wait longer to benefit from it”. 

4-month TB treatment for children
Mother of 19-month-old Essa greets an MSF patient support supervisor before leaving the MSF-supported Programmatic Management of Drug-Resistant Tuberculosis (PMDT) site in Gujranwala, Punjab, where Essa is receiving an 18-month treatment for drug-resistant tuberculosis.
MSF

Treatment outcomes and remaining challenges

In this prospective study involving 214 children receiving care in health facilities in Uganda and the Philippines, nearly three-quarters (74%) were identified as eligible for the 4-month regimen at the start of treatment. Treatment outcomes were highly positive, with 95% of children successfully completing treatment. Healthcare workers and caregivers welcomed the shorter treatment, citing fewer clinic visits and a reduced burden on families. However, challenges remain, including limited access to chest X-rays, gaps in healthcare worker training and high staff turnover.

What governments need to do, according to the study coordinator

“Our experience of implementing the four-month TB treatment regimen for children shows that it can be successfully introduced into routine care, leaving no reason to delay its wider roll-out,” said Dr Maria Namulwana, Study Coordinator, MSF/Epicentre Uganda. “But to make this a reality for more children, governments must go beyond updating guidelines and invest in training healthcare workers, strengthening diagnostic services, ensuring access to child-friendly medicines and supporting families throughout treatment.” 

4-month TB treatment for children
Seven-year-old Mum-e-Hibba and her mother share their treatment experience with MSF staff at the MSF TB clinic at the Rural Health Centre Baldia, District Kemari, Karachi where Mum-e-Hibba is receiving treatment for tuberculosis.
MSF

MSF’s call on governments and donors

TB remains the world's deadliest infectious disease, with children being hit hard. As per WHO’s 2026 Global TB Report, half of the children under 5 years old have missed TB diagnosis in 2025 and could not access treatment in 2025, a statistic that has not improved from previous years.

“Every three minutes, a child dies of TB. We cannot keep leaving children behind when effective medical tools are already within reach, including reducing treatment duration for children with non-severe TB from 6 months to 4 months”, said Dr Ana Paula Cavalheiro, Leader of the global TB platform of MSF.  “It is high time governments and donors step up and ensure that children can be diagnosed early and receive the best possible treatment and care, no matter where they live.”